European Alzheimer’s Medication Market Headed for Slowdown, Will Revive by 2015

Life Science Investing News

Frost & Sullivan announced that the patents for the four drugs that the European Medicines Agency has approved for Alzheimer’s disease will expire in 2015, meaning that there will probably be a brief slowdown in Europe’s market for Alzheimer’s medication. Opportunities are expected to arise again between 2015 and 2018 on the back of innovative new therapies.

Frost & Sullivan reported that the patents for the four drugs that the European Medicines Agency has approved for Alzheimer’s disease will expire in 2015, meaning that there will probably be a brief slowdown in Europe’s market for Alzheimer’s medication. Opportunities are expected to arise again between 2015 and 2018 on the back of innovative new therapies.

As quoted in the market news:

New analysis from Frost & Sullivan … estimates the market to earn $1.80 billion in 2012 and reach $4.78 billion in 2019, growing at a compound annual growth rate (CAGR) of 15.1% from 2012-2019.
A key challenge at present is the looming patent expiry of key blockbuster drugs including Aricept, Exelon Patch and Ebixa. Their going off-patent is set to unleash a flood of cheaper generic equivalents that will result in lowered market revenues.
The accurate diagnosis of AD, especially in the early stages and monitoring of disease progression, will play a vital role in promoting proper market segmentation and positioning of drugs by market participants.

Click here to read the full Frost & Sullivan report.

europe generic Life Science Investing